Bicalieva (Bicalutamide) Tablet

Description

Description

This page contains brief details about the drug bicalutamide, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Bicalutamide is an oral non-steroidal anti-androgenic drug used to treat stage 2 metastatic prostate cancer. It was approved by the FDA on 19 December 2008.

Mechanism of Action of Bicalutamide

Antiandrogens counter male hormonal action by interfering with the synthesis of androgens or by blocking their receptors. Bicalutamide, anti-androgen, competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin, which stimulate the growth of normal and malignant prostatic tissues. Thereby reducing the growth and spread of cancer.

Uses of Bicalutamide

Bicalutamide is in a class of medications called nonsteroidal antiandrogens. It works by blocking the effect of androgen (a male hormone) to stop the growth and spread of cancer cells in the prostate gland (located just below the bladder in men). It is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) agonist to treat Stage D2 metastatic carcinoma of the prostate.

Bicalutamide Dosage available

Bicalutamide is a prescribed drug available as a 50 mg tablet. The recommended dose in combination with a luteinizing hormone-releasing hormone (LHRH) analog is one 50 mg tablet once daily (morning or evening) to treat stage D2 metastatic prostate cancer. Your healthcare physician will prescribe the medicine based on the condition.